Combination Therapy with Hormone Replacement and Alendronate for Prevention of Bone Loss in Elderly Women: A Randomized Controlled Trial

JAMA

Volumn 289, Issue 19, 2003, Pages 2525-2533

  Greenspan, Susan L ^a,c   Resnick, Neil M ^a   Parker, Robert A ^b  

^a UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

^b CENTER FOR BIOSTATISTICS IN AIDS RESEARCH   (United States)

^c UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; CALCIUM; CONJUGATED ESTROGEN; MEDROXYPROGESTERONE; VITAMIN D; MEDROXYPROGESTERONE ACETATE; PROGESTERONE DERIVATIVE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MASS; BONE MINERAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSPHAGIA; ELDERLY CARE; ESOPHAGITIS; FEMALE; FEMUR; HEART INFARCTION; HEARTBURN; HIP; HORMONE SUBSTITUTION; HUMAN; INDIGESTION; LUMBAR SPINE; MAJOR CLINICAL STUDY; OSTEOLYSIS; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; PROPHYLAXIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME; TREATMENT PLANNING; VERTEBRA; VITAMIN SUPPLEMENTATION; DRUG COMBINATION; ESTROGEN THERAPY;

AGED; AGED, 80 AND OVER; ALENDRONATE; BONE DENSITY; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTROGEN REPLACEMENT THERAPY; ESTROGENS, CONJUGATED (USP); FEMALE; HUMANS; MEDROXYPROGESTERONE 17-ACETATE; OSTEOPOROSIS, POSTMENOPAUSAL; PROGESTERONE CONGENERS;

EID: 0037974904     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.289.19.2525     Document Type: Article

References (41)

1. Cummings SR, Melton LJI. Epidemiology and outcomes of osteoporotic fractures. Lancet. 2002;359:1761-1767.
2. NIH consensus declares osteoporosis a major public health issue. Osteoporosis Rep. 2000;16:1.
3. Writing Group for the Women's Health Initiative Investigators. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA. 2002;288:321-333.
4. Faulkner KG. Bone matters: are density increases necessary to reduce fracture risk? J Bone Miner Res. 2000;15:183-187.
5. Marshall D, Johnell O, Wedel H. Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ. 1996;312:1254-1259.
6. Wasnich RD, Miller PD. Antifracture efficacy of antiresorptive agents are related to changes in bone density. J Clin Endocrinol Metab. 2000;85:231-236.
7. Hochberg MC, Greenspan S, Wasnich RD, Miller P, Thompson DE, Ross PD. Changes in bone density and turnover explain the reductions in incidence of nonvertebral fractures that occur during treatment with antiresorptive agents. J Clin Endocrinol Metab. 2002;87:1586-1592.
8. Cummings SR, Karpf DB, Harris F, et al. Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs. Am J Med. 2002;112:281-289.
9. Bone HG, Greenspan SL, McKeever C, et al. Alendronate and estrogen effects in postmenopausal women with low bone mineral density. J Clin Endocrinol Metab. 2000;85:720-726.
10. Looker AC, Johnston CC Jr, Wahner HW, et al. Prevalence of low femoral bone density in older US women from NHANES III. J Bone Miner Res. 1995;10:796-802.
11. Dawson-Hughes B, Jacques P, Shipp C. Dietary calcium intake and bone loss from the spine in healthy postmenopausal women. Am J Clin Nutr. 1987;46:685-687.
12. Regan MM, Emond SK, Attardo MJ, Parker RA, Greenspan SL. Why do elderly women discontinue hormone replacement therapy? J Womens Health Gender Based Med. 2001;10:343-350.
13. Greenspan SL, Maitland LA, Myers ER, Krasnow MB, Kido TH. Femoral bone loss progresses with age: a longitudinal study in women over age 65. J Bone Miner Res. 1994;9:1959-1965.
14. Greenspan SL, Maitland-Ramsey L, Myers E. Classification of osteoporosis in the elderly is dependent on site-specific analysis. Calcif Tissue Int. 1996;58:409-414.
15. Lu Y, Mathur AK, Blunt BA, et al. Dual X-ray absorptiometry quality control: comparison of visual examination and process-control charts. J Bone Miner Res. 1996;11:626-637.
16. Lawton MP, Brody EM. Assessment of older people: self-maintaining and instrumental activities of daily living. Gerontologist. 1969;9:179-186.
17. Folstein MF, Folstein SE, McHugh PR. Mini mental state. J Psychiatr Res. 1975;12:189-198.
18. Greenspan SL, Parker RA, Ferguson L, Rosen HN, Maitland-Ramsey L, Karpf DB. Early changes in biochemical markers of bone turnover predict the longterm response to alendronate therapy in representative elderly women: a randomized clinical trial. J Bone Miner Res. 1998;13:1431-1438.
19. Greendale GA, Wells B, Marcus R, Barrett-Connor E, for the Postmenopausal Estrogen/ Progestin Interventions Trial Investigators. How many women lose bone mineral density while taking hormone replacement therapy? results from the Postmenopausal Eastrogen/Progestin Interventions trial. Arch Intern Med. 2000;160:3065-3071.
20. Kanis JA, Melton LJ, III, Christiansen C, Johnston CC, Khaltaev N. The diagnosis of osteoporosis. J Bone Miner Res. 1994;9:1137-1141.
21. Kanis JA, for the WHO Study Group. Assessment of fracture risk and its application to screening for postmenopausal osteoporosis: synopsis of a WHO report. Osteoporos Int. 1994;4:368-381.
22. Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. JAMA. 1995;273:199-208.
23. Villareal DT, Binder EF, Williams DB, Schechtman KB, Yarasheski KE, Kohrt WM. Bone mineral density response to estrogen replacement in frail elderly women: a randomized controlled trial. JAMA. 2001;286:815-820.
24. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.
25. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial. JAMA. 1998;280:2077-2082.
26. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA. 1999;282:637-645.
27. Harris ST, Watts NB, Genant HK, et al. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. JAMA. 1999;282:1344-1352.
28. Reginster J-Y, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int. 2000;11:83-91.
29. Palomba S, Orio FJ, Colao A, et al. Effect of estrogen replacement plus low-dose alendronate treatment on bone density in surgically postmenopausal women with osteoporosis. J Clin Endocrinol Metab. 2002;87:1502-1508.
30. Harris S, Eriksen EF, Davidson M, et al. Effects of combined risedronate and hormone replacement therapies on bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2002;86:1890-1897.
31. Liberman UA, Weiss SR, Broll J, et al. Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis: the Alendronate Phase III Osteoporosis Treatment Study Group. N Engl J Med. 1995;333;1437-1443.
32. Hulley S, Grady D, Buch T, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA. 1998;280:605-613.
33. Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density. JAMA. 1996;276:1389-1396.
34. Nelson HD, Humphrey LL, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy. JAMA. 2002;288:872-881.
35. Hulley S, Furberg C, Barrett-Connor E, et al. Noncardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA. 2002;288:58-66.
36. Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy: Heart and Estrogen/Progestin Replacement Study Follow-up (HERS II). JAMA. 2002;288:49-57.
37. Kanaya AM, Herrington D, Vittinghoff E, et al. Glycemic effects of postmenopausal hormone therapy: the Heart and Estrogen/Progestin Replacement Study: a randomized, double-blind, placebo-controlled trial. Ann Intern Med. 2003;138:1-9.
38. Wilson PWF. Lower diabetes risk with hormone replacement therapy: an encore for estrogen? Ann Intern Med. 2003;138:69-70.
39. LeBlanc ES, Janowsky J, Chan BKS, Nelson HD. Hormone replacement therapy and cognition: a systematic review and meta-analysis. JAMA. 2001;285:1489-1499.
40. Hlatky MA, Boothroyd D, Vittinghoff E, Sharp P, Whooley MA, for the HERS Research Group. Quality-of-life and depressive symptoms in postmenopausal women after receiving hormone therapy: results from the Heart and Estrogen/Progestin Replacement Study (HERS) trial. JAMA. 2002;287:591-597.
41. Kuchel GA, Tannenbaum C, Greenspan SL, Resnick NM. Can variability in the hormonal status of elderly women assist in the decision to administer estrogens? J Womens Health Gender Based Med. 2001;10:109-116.